News
Media
Medical World NewsPodcastsVideosInsightsPeer ExchangeMedia DayNews NetworkRoundtables
Conference
Conference CoverageConference Listing
Publication
More
CME/CE
Partners
Resources
Interactive ToolsSpecial ProjectsSponsored
Contribute
Case StudiesWriters and Mentors

Subscribe

  • News
  • Media
  • Conference
  • Publication
  • CME/CE
  • Partners
  • Resources
  • Contribute
  • Subscribe
  • Antimicrobial Stewardship
  • Blood-Borne Diseases
    • Ebola
    • HCV / Hepatitis
  • Coronavirus / COVID
  • Food Borne Infection / Food Safety
    • E. Coli
    • Food Safety
    • Listeria
    • Salmonella
  • Fungal Infections
    • Candida auris
  • Gastrointestinal Infections
    • C. Difficile
    • H. Pylori
    • Norovirus
  • Healthcare Associated Infections (HAI)
  • Prevention
    • Antibiotics
    • Immunizations
    • Vaccines
  • Respiratory Infections
    • Community-Acquired Pneumonia
    • Measles
    • Influenza
  • Sexually Transmitted Diseases
    • HIV / AIDS
    • HPV
    • HSV
    • PrEP
  • Skin & Soft Tissue Diseases
    • MRSA
  • Zoonotic & Vector-Borne Diseases
    • Lyme Disease
    • ZIKA
Spotlight -
Antimicrobial Stewardship|
Bench to Bedside With SIDP|
C. difficile |
Clinical Corner|
Fungal Infections|
Hepatitis|
RSV: A New Era in Prevention
Advertisement

Susie Lee, PharmD (student)

Advertisement

Articles by Susie Lee, PharmD (student)

New Flucelvax Quadrivalent Influenza Vaccine Approved by FDA

BySusie Lee, PharmD (student)
June 14th 2016

Sequirus recently announced that the US Food and Drug Administration (FDA) has approved Flucelvax Quadrivalent influenza vaccine.

Advertisement

Latest Updated Articles

  • New Flucelvax Quadrivalent Influenza Vaccine Approved by FDA
    New Flucelvax Quadrivalent Influenza Vaccine Approved by FDA

    Published: June 14th 2016 | Updated:



Advertisement
Advertisement

Trending on Contagion Live

1

Oral Carbapenem Tebipenem HBr Demonstrates Non-Inferiority to IV Therapy in Phase III PIVOT-PO Trial

2

New Data Highlight Adult Pneumococcal Serotypes with Greater Antibiotic Resistance and Disease Burden Covered by Merck’s Vaccine

3

Introducing Cefiderocol Earlier in Difficult-to-Treat-Infections

4

Developing a COVID-19 Vaccine Alternative

5

Lori Handy, MD, MSCE, Discusses New Era of Dynamic, Trust-Based Health Communication

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Do Not Sell My Information
  • Privacy
  • Terms & Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us